Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Advanced Cancer

Interventions

DRUG

personalized vaccine

Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.

DRUG

Pembrolizumab

200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.

Trial Locations (1)

UCSD Medical Center, San Diego

All Listed Sponsors

lead

Ezra Cohen

OTHER